ATE284701T1 - Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren - Google Patents

Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Info

Publication number
ATE284701T1
ATE284701T1 AT01913267T AT01913267T ATE284701T1 AT E284701 T1 ATE284701 T1 AT E284701T1 AT 01913267 T AT01913267 T AT 01913267T AT 01913267 T AT01913267 T AT 01913267T AT E284701 T1 ATE284701 T1 AT E284701T1
Authority
AT
Austria
Prior art keywords
vegf
cells
tumor
screening
methods
Prior art date
Application number
AT01913267T
Other languages
English (en)
Inventor
Marc Ludwig Achen
Steven Ludwig Stacker
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE284701T1 publication Critical patent/ATE284701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
AT01913267T 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren ATE284701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18636100P 2000-03-02 2000-03-02
PCT/US2001/006791 WO2001064235A1 (en) 2000-03-02 2001-03-02 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d

Publications (1)

Publication Number Publication Date
ATE284701T1 true ATE284701T1 (de) 2005-01-15

Family

ID=22684635

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Country Status (12)

Country Link
US (1) US20010038842A1 (de)
EP (1) EP1259248B1 (de)
JP (1) JP2003525248A (de)
KR (1) KR20020080461A (de)
AT (2) ATE533056T1 (de)
AU (1) AU4194601A (de)
CA (1) CA2401665A1 (de)
DE (1) DE60107815T2 (de)
ES (2) ES2234818T3 (de)
NZ (1) NZ520546A (de)
PT (1) PT1259248E (de)
WO (1) WO2001064235A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1353952B1 (de) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
EP1425580A4 (de) * 2001-07-12 2006-03-29 Ludwig Inst Cancer Res Materialien und verfahren mit lymphatischen endothelzellen
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078778A2 (en) 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
CN103739710B (zh) * 2014-01-26 2015-12-09 中国人民解放军军事医学科学院基础医学研究所 一种抗vegf抗体及其应用
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733322B2 (en) * 1996-07-15 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Novel VEGF-like factor
ES2251740T3 (es) * 1996-08-23 2006-05-01 Ludwig Institute For Cancer Research Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
KR100628697B1 (ko) * 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
JP4632543B2 (ja) * 1998-12-21 2011-02-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 切断ｖｅｇｆ−ｄの抗体及びその利用法
PL352859A1 (en) * 1999-06-11 2003-09-08 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
ES2377119T3 (es) 2012-03-22
NZ520546A (en) 2004-05-28
ATE533056T1 (de) 2011-11-15
DE60107815D1 (de) 2005-01-20
PT1259248E (pt) 2005-04-29
WO2001064235A1 (en) 2001-09-07
EP1259248A1 (de) 2002-11-27
US20010038842A1 (en) 2001-11-08
KR20020080461A (ko) 2002-10-23
AU4194601A (en) 2001-09-12
EP1259248A4 (de) 2003-05-28
ES2234818T3 (es) 2005-07-01
JP2003525248A (ja) 2003-08-26
DE60107815T2 (de) 2005-12-08
CA2401665A1 (en) 2001-09-07
EP1259248B1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
ATE284701T1 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
Stohrer et al. Oncotic pressure in solid tumors is elevated
Whyte et al. Wnt signaling and injury repair
Spiller et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds
Kruger et al. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers
Demicheli et al. The effects of surgery on tumor growth: a century of investigations
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
Tian et al. Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
Vikey et al. Primary malignant melanoma, of head and neck: a comprehensive review of literature
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
Reis-Filho et al. Maspin expression in normal skin and usual cutaneous carcinomas
Smeester et al. Effects of different electroacupuncture scheduling regimens on murine bone tumor-induced hyperalgesia: sex differences and role of inflammation
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
Dessy et al. Scalp reconstruction using dermal induction template: state of the art and personal experience
Boueuf et al. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
ATE426813T1 (de) Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE499611T1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
Arjama Establishment of patient-derived cancer models from melanoma for functional drug sensitivity and resistance testing

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259248

Country of ref document: EP

REN Ceased due to non-payment of the annual fee